Suicidal Intent due to Vareniclin Use Case Report
DOI:
https://doi.org/10.17986/blm.2014193801Keywords:
varenicline treatment, forensic medicine, suicideAbstract
Varenicline is the most effective pharmacological treatment currently used to for smoking cessation treatment. It is a selective partial agonist for α2-β2 nicotinic acetylcholine receptors. Although it is highly successful in smoking cessation, it is responsible for serious neuropsychiatric side effects. One of the most serious side effects in patients using Varenicline is increased suicidal intent and tendency. Here, we report a 31 years old female patient who developed suicidal intent because of Vareniclin use; therefore, attract professionals attention to the relationship between the use of Vareniclin and depression symptoms, suicide intent and suicidality. In this context, we believe that use of Vareniclin should be questioned in the patients admitted to emergency department with suicide attempts or in completed suicide cases subjected to forensic investigation.
Key words: Varenicline treatment, forensic medicine, suicide.
References
http://www.who.int/gho/tobacco/en/ Erişim Tarihi: 10.08.2014.
Sayan İ, Tekbaş ÖF, Göçgeldi E, Paslı E, Babayiğit M. Bir eğitim hastanesinde görev yapan hemşirelerin sigara içme profilinin belirlenmesi. Genel Tıp Dergisi. 2009; 19 (1): 9-15.
Şahin Ü, Öztürk M, Ünlü M, Uşkun E, Akkaya A. Üniversite öğrencilerinin sigara kullanım ve bağımlılık düzeylerini etkileyen faktörlerin irdelenmesi. Türkiye Klinikleri Arc Lung. 2000; 1 (2): 1-5.
Brown J, Hajek P, McRobbie H, Locker J, Gillison F, McEwen A et all. Cigarette craving and withdrawal symptoms during temporary abstinence and the effect of nicotine gum. Psychopharmacology. 2013; 22(9): 209-218.
Ahmed A, Ali A, Kramers C, Harmark L, Burger D, Verhoeven W. Neuropsychiatric Adverse Events of Varenicline A Systematic Review of Published Reports. Journal of Clinical Psychopharmacology. 2013; 1 (33): 55-62.
Swanson AN, Shoptaw S, Heinzerling KG, Wade AC, Worley M, McKracken J et al. Up in Smoke? A Preliminary Open-Label Trial of Nicotine Replacement Therapy and Cognitive Behavioral Motivational Enhancement for Smoking Cessation Among Youth in Los Angeles. Substance Use & Misuse. 2013; 14 (48):1553-15.
Wartburd M, Raymond V, Paradis PE. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada. International Journal of Clinical Practice. 2014; 5 (68): 639-646.
Rao J, Shankar PK. Varenicline: For smoking cessation. Kathmandu University Medical Journal (2009); 26 (7): 162-164.
Purvis LT. Nelson LA, Mambourg ES. Varenicline use in patients with mental illness: an update of the evidence Expert Opin Drug Saf. 2010; 9 (3): 471-82.
Tonstand S, Davies S, Flammer M, Russ C, Hughes C. Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline. Drug Safety. 2010: 33 (4); 289-301.
Dilektaşlı A. Sigara Bağımlılığının Farmakolojik Tedavisi. Türkiye Klinikleri J Pulm Med-Special Topics 2012;5(2):43-50.
Ceylan E, Yanık M, Gencer M. Harran Üniversitesi’ne Kayıt Yaptıran Öğrencilerin Sigaraya Karşı Tutumlarını Etkileyen Faktörler. Türk Toraks Dergisi. 2005; 2 (6): 144-150.
Corrao MA, Guindon GE, Sharma N, Shokoohi DF; eds. Tobacco Control Country Profiles. Atlanta GA: American Cancer Society; 2000:344.
Karlıkaya C, Öztuna F, Solak ZA, Özkan M, Örsel O. Tütün Kontrolü. Toraks Dergisi. 2006; 7 (1): 51-64.
Kasliwall R, Wilton WL, Shakir S. Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England. Drug Safety. 2009; 6 (32): 499-507.
FDA requires new boxed warnings for the smoking cessation drugs chantix and zyban. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2009.
Medicines and Healthcare Products Regulatory Agency. Drug analysis print_varenicline. Erişim Adresi: http://www.mhra.gov.uk/ Safety information/ Reportingsafetyproblems/Medicines/Reportingsuspectedadversedrugreactions/Druganalysisprints/index.htm. Erişim Tarihi: 10.08.2014.
Harrison M, Ashton J. Psychiatric Adverse Events Associated with Varenicline. Drug Sof. 2011; 34 (9): 763-772.
Kintz P, Evans J, Villain M, Cirimele V. Smoking Cessation with Varenicline: A Suicidal Fatality. Journal of Analytical Toxicology. 2009; 33: 118-120.
Steve CP, Letter A, Piette MH, Lamber W. Fatality following a suicidal overdose with varenicline. International Journal of Legal Medicine. 2013; 1 (127): 85-91.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 Özge Gülmez- Ramazan Akçan
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal and content of this website is licensed under the terms of the Creative Commons Attribution (CC BY) License. The Creative Commons Attribution License (CC BY) allows users to copy, distribute and transmit an article, adapt the article and make commercial use of the article. The CC BY license permits commercial and non-commercial re-use of an open access article, as long as the author is properly attributed.
